Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repare Therapeutics Inc (NQ: RPTX ) 3.430 +0.080 (+2.39%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Repare Therapeutics Inc < Previous 1 2 3 4 5 6 Next > Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 February 15, 2024 From Repare Therapeutics Inc. Via Business Wire Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month February 13, 2024 Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. Via Benzinga Repare Therapeutics to Regain Global Rights to Camonsertib February 12, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment January 25, 2024 From Repare Therapeutics Inc. Via Business Wire Recap: Repare Therapeutics Q3 Earnings November 09, 2023 Via Benzinga Wall Street Thinks This Cathie Wood Stock Could Jump by 187% August 16, 2023 This small-cap biotech stock holds enormous growth potential. Via The Motley Fool Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones January 08, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer January 04, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans December 29, 2023 From Repare Therapeutics Inc. Via Business Wire Analyst Expectations for Repare Therapeutics's Future June 09, 2023 Via Benzinga Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor November 15, 2023 From Repare Therapeutics Inc. Via Business Wire These Biotech Stocks Could Double Your Money, According To Analysts November 09, 2023 Via Benzinga Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results November 09, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast November 07, 2023 From Repare Therapeutics Inc. Via Business Wire $2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying November 06, 2023 The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session November 06, 2023 Via Benzinga Repare Therapeutics to Participate in Two Upcoming Investor Conferences November 06, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib October 13, 2023 From Repare Therapeutics Inc. Via Business Wire Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 09, 2023 Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... Via Benzinga Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 03, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics September 19, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference September 06, 2023 From Repare Therapeutics Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session August 10, 2023 Via Benzinga Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10 August 10, 2023 Via Investor Brand Network Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results August 09, 2023 From Repare Therapeutics Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2023 June 09, 2023 Via Benzinga Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials June 08, 2023 Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected Via Benzinga Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference June 08, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials June 07, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors June 06, 2023 From Repare Therapeutics Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.